Gan & Lee Pharmaceuticals.

This study tests a single dose of an investigational diabetes drug called GZR4 in 36 adults with diabetes who also have mild, moderate, or severe liver impairment. The goal is to see how the drug moves through the body and whether it is safe in people with different levels of liv…

This study compares a new once-weekly insulin (GZR4) with a standard daily insulin (glargine U100) in 580 adults with type 2 diabetes who already use mealtime insulin. The goal is to see if the weekly shot works as well or better at controlling blood sugar, with fewer injections …

This study tests an experimental injection called GZR18 in 630 adults who are obese or overweight. Participants receive either the drug or a placebo to see how much weight they lose and if it is safe. The goal is to find a new treatment option for weight management.

This study tests an experimental injection called GZR18 in 274 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. The main goal is to see if the drug safely lowers blood sugar levels over time. Participants will be randomly as…

This study tests a new insulin called GZR4 that is given once a week, compared to a standard daily insulin (glargine), in adults with type 2 diabetes who have never used insulin before. About 580 participants will receive either the weekly shot or the daily shot, along with other…

This study tests a new insulin called GZR4 that is taken once a week, compared to a daily insulin (degludec), in adults with type 2 diabetes who already use basal insulin. The goal is to see if the weekly shot works as well or better at controlling blood sugar and is safe. About …

This study tests a new medicine called GZR18 for people with type 2 diabetes whose blood sugar is not well controlled with current pills. About 1,100 Chinese adults will receive either GZR18 or another diabetes drug to see which works better at lowering blood sugar and body weigh…